Lumicell

Executive Summary

Lumicell is a commercial-stage medical technology company dedicated to improving cancer surgery outcomes. Its flagship product, the LumiSystem, received FDA approval for use in breast cancer lumpectomy. The system comprises the LUMISIGHT optical imaging agent and the Lumicell Direct Visualization System (DVS), enabling surgeons to detect and remove residual cancer in real-time during surgery. This innovation addresses a critical unmet need, as up to 20-40% of breast cancer patients require re-excision due to positive margins. By illuminating residual tumor tissue, Lumicell aims to reduce re-operation rates, lower healthcare costs, and improve patient outcomes. The company is now focused on commercial adoption in the United States, targeting leading cancer centers and hospitals. Lumicell's technology has the potential to expand beyond breast cancer into other solid tumors, such as colorectal, lung, and ovarian cancers, where intraoperative margin assessment is similarly critical. The company's early mover advantage in the intraoperative imaging space, combined with a strong intellectual property portfolio, positions it well for growth. However, as a private company, financial details are limited, and commercial success depends on reimbursement coverage, surgeon adoption, and positive real-world evidence. With a validated FDA-approved platform and a clear value proposition, Lumicell is poised to become a standard of care in cancer surgery.

Upcoming Catalysts (preview)

• Q3 2026First commercial adoption contracts with major cancer centers75% success
• Q4 2026Initiation of clinical trial for expansion into colorectal or other solid tumors60% success
• Q2 2027Publication of long-term outcomes from the LUMINARY breast cancer study85% success